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To investigate whether measles, mumps, and rubella 
(MMR) vaccine has positive non-specific effects in a 
high income setting and to compare rates of hospital 
admissions for infections between children aged ≤2 
years who received live MMR vaccine and those who 
received an inactivated vaccine against diphtheria, 
tetanus, pertussis, polio, and Haemophilus influenzae 
type b (DTaP-IPV-Hib) as their most recent vaccination.
DESIGN
Nationwide population based cohort study.
SETTING
In the Netherlands, DTaP-IPV-Hib+pneumococcal 
vaccination (PCV) is recommended at ages 2, 3, 4, 
and 11 months and MMR + meningococcal C (MenC) 
vaccination at age 14 months. Data from the national 
vaccine register were linked to hospital admission 
data.
PARTICIPANTS
1 096 594 children born in 2005-11 who received the 
first four DTaP-IPV-Hib+PCV vaccines.
MAIN OUTCOME MEASURES
Hazard ratio for admission to hospital for infection in 
children with MMR+MenC compared with the fourth 
DTaP-IPV-Hib+PCV as their most recent vaccination. 
Cox regression was performed with most recent 
vaccination as time dependent variable, adjusted 
for potential confounders. Analyses were repeated 
with admission for injuries or poisoning as a negative 
control outcome. In addition, rate of admission for 
infection was compared between the fourth and third 
DTaP-IPV-Hib+PCVas most recent vaccination.
RESULTS
Having had MMR+MenC as the most recent 
vaccination was associated with a hazard ratio of 0.62 
(95% confidence interval 0.57 to 0.67) for admission 
to hospital for infection and 0.84 (0.73 to 0.96) for 
injuries or poisoning, compared with the fourth DTaP-
IPV-Hib+PCV as most recent vaccination. The fourth 
DTaP-IPV-Hib+PCV as most recent vaccination was 
associated with a hazard ratio of 0.69 (0.63 to 0.76) 
for admission to hospital for infection, compared 
with the third DTaP-IPV-Hib+PCV as most recent 
vaccination.
CONCLUSIONS
Healthy vaccinee bias could at least partly explain 
the observed lower rate of admission to hospital 
with infection after MMR vaccination. The lower rate 
is associated with receipt of any additional vaccine, 
not specifically MMR vaccine. This emphasises the 
caution required in the interpretation of findings 
from observational studies on non-specific effects of 
vaccination.
Introduction
Vaccines against measles; diphtheria, pertussis, and 
tetanus (DTP); and polio have led to large declines in 
morbidity and mortality from the targeted diseases.12 
It has been suggested that these vaccines could also 
affect morbidity and mortality from infections other 
than those targeted by the vaccines—that is, that they 
have non-specific effects.3 Several studies observed 
beneficial non-specific effects of live attenuated 
vaccines (such as measles and BCG) and deleterious 
non-specific effects of inactivated vaccines (such as 
DTP vaccine), with, in general, stronger effects in 
girls than in boys.4 5 6 7 8 9 10 Moreover, the sequence 
of vaccination could be important. Receipt of a live 
attenuated measles vaccine after an inactivated DTP 
vaccine might be associated with lower morbidity and 
mortality, compared with receipt of a DTP vaccine after 
or at the same time as a measles vaccine.11 12 13 14 15 16 
Which immunological mechanisms could underlie 
these potential non-specific effects of vaccination 
on susceptibility to infectious disease is currently 
unknown. Trained innate immunity, which depends 
on epigenetic reprogramming of innate immune cells, 
could explain some of the non-specific effects.1718 
Another potential mechanism is through T cell 
mediated cross reactivity.18
Few studies on non-specific effects have been 
performed in high income countries, which have low 
rates of infant mortality from infectious diseases. 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Live attenuated vaccines (such as measles) could have beneficial non-specific 
effects and inactivated vaccines (such as DTP) could have deleterious non-specific 
effects
The evidence for non-specific effects of vaccines remains weak as most evidence 
comes from observational studies that are vulnerable to bias
WhAT ThIS STudy AddS
Healthy vaccinee bias at least partly explains the observed lower rate of hospital 
admission for infection after MMR vaccination; this lower rate is associated with 
receipt of any additional vaccine and not specifically with MMR
The presence of non-specific effects of MMR vaccination cannot be excluded, but 
the possible non-specific effects cannot be distinguished from bias
The findings emphasise the importance of caution in the interpretation of 
findings from observational studies on non-specific effects of vaccination
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The public health relevance of non-specific effects of 
vaccines in high income countries is largely unknown. 
Two nationwide Danish studies reported measles, 
mumps, and rubella (MMR) vaccine to be associated 
with a 16% lower rate of hospital admissions for 
infectious disease10 and a 22% lower rate of hospital 
contacts for respiratory syncytial virus19 compared 
with DTP-IPV-Hib as most recent vaccine. No 
differences were observed between boys and girls. The 
Danish studies used timing of MMR vaccination as the 
(time varying) exposure.
Most of the evidence on non-specific effects of 
vaccines originates from observational studies, which 
are prone to bias.20 An example is healthy vaccinee 
bias (also known as healthy user bias or frailty bias), 
which occurs when children who are more susceptible 
to illness are vaccinated later or not at all, resulting 
in an overestimation of the beneficial effect of the 
next vaccination. Recently, two systematic reviews of 
the potential non-specific effects of DTP and measles 
vaccines, which were commissioned by the World 
Health Organization strategic advisory group of experts 
(SAGE), were published.21 Findings suggest that receipt 
of measles vaccine reduces overall mortality more than 
would be expected through the effects on the targeted 
disease, while DTP vaccination might be associated with 
an increase in all cause mortality.21 As most evidence 
came from observational studies (10 observational 
studies for DTP11 12 22 23 24 25 26 27 28; four trials6 29 30 31 
and 17 observational studies11 12 13 22 28 32 33 34 35 36 37 38 
39 40 41 42 for measles), however, the conclusion was that 
these findings should be interpreted with caution. 
We set out to reproduce the findings of the Danish 
studies on non-specific effects of MMR vaccination in 
a population based nationwide cohort study of more 
than a million Dutch children using similar methods. 
We investigated the rate of hospital admissions related 
to infectious disease after receipt of the live attenuated 
MMR vaccine (given at the same time as vaccination 
against meningococcal disease group C, MenC) versus 
inactivated DTP containing vaccine (also includes 
vaccinations against polio (inactivated polio vaccine, 
IPV) and Haemophilus influenzae type b and given at 
the same time as a vaccination against pneumococcal 
disease) as most recent vaccine. In addition, we 
explored whether healthy vaccinee bias was present.
Methods
Study design
The Dutch national immunisation programme 
was implemented in 1957 and is coordinated and 
evaluated by the Dutch National Institute for Public 
Health and the Environment. Table 1 shows the 
recommended vaccines included in the programme in 
the first 24 months of life, and table A in appendix 1 
shows the years of introduction into the programme. 
The DTaP-IPV-Hib vaccine, recommended at ages 2, 
3, 4, and 11 months, consists of vaccinations against 
diphtheria, tetanus, pertussis (acellular), polio, and 
conjugate vaccine against H influenzae type b (Hib) 
and is administered simultaneously with a multivalent 
conjugate vaccination against pneumococcal disease 
(PCV). The vaccination against MMR is recommended 
at age 14 months and administered simultaneously 
with vaccination against meningococcal disease 
serogroup C (MenC). Only the MMR vaccine is a live 
vaccine; the other vaccines are inactivated/non-live 
vaccines.
Vaccination data
In 2005, an electronic national immunisation register 
“Præventis” was implemented in the Netherlands. 
The register is linked to the population register. This 
means that all children and young people aged under 
19 who are officially registered in the Netherlands 
are included in the immunisation register. Praeventis 
does not include undocumented children living in 
the Netherlands. Parents receive invitation letters 
automatically created by Præventis to get their 
child(ren) vaccinated at a specific date and time at a 
healthy children clinic near their homes according to 
the immunisation programme. Data on administered 
vaccinations (that is, vaccine characteristics, dose, 
date of administration) are entered in Præventis.43
Hospital admission data
The national medical register administeredby Dutch 
hospital data provided data on hospital admissions 
from 1 January 2005 to 31 December 2012. Dutch 
hospital data requests hospitals and university medical 
centres in the Netherlands to voluntarily supply data 
on admissions. The coverage of all hospital admissions 
decreased with time, with 3% missing in 2005 to 25% 
in 2012.44
Primary and secondary discharge diagnoses and 
dates of admissions were available from the register. 
Diagnoses were coded according to the ICD-9-CM 
(international classification of diseases, ninth revision, 
clinical modification). We included upper respiratory 
infections, lower respiratory infections, gastrointestinal 
infections, and other infections (table B in appendix 
1). In the main analysis we included only hospital 
admissions that lasted more than one day (and thus 
included an overnight stay) to exclude day admissions 
related to planned examinations and surgeries. In a 
sensitivity analysis, we included all admissions.
Covariates
Præventis provided data on sex, parents’ country 
of birth, and postcode, and Statistics Netherlands 
Table 1 | Vaccines recommended in first 24 months of life 
according to Dutch national immunisation programme
Age (months) Vaccinations
2 DTaP-IPV-Hib(-HepB since August 2011)+PCV
3 DTaP-IPV-Hib(-HepB since August 2011)+PCV
4 DTaP-IPV-Hib(-HepB since August 2011)+PCV
11 DTaP-IPV-Hib(-HepB since August 2011)+PCV
14 MMR + MenC
DTaP=diphtheria, tetanus, pertussis (acellular); HepB=hepatitis 
B; Hib=H influenzae type b; IPV=inactivated polio vaccine; 
MenC=meningococcal disease group C; MMR=measles, mumps, rubella; 
PCV=pneumococcal conjugate vaccine.
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provided data on death, migration, and parental 
educational level. Parental educational level was 
classified as low (elementary education or pre-
vocational education), medium (senior general 
secondary education, pre-university education, or 
vocational education), or high (college or university). 
The Netherlands perinatal registry provided data on 
birth weight, gestational age, maternal age, and parity 
(as a proxy for number of siblings).
Linkage of data sources
The population register (the municipal personal 
records database) was the main database to which 
all databases were linked to get a unique anonymised 
number with which the different databases could be 
linked. Of all 1 357 461 children that were included in 
Præventis, 1 356 926 (>99%) were successfully linked 
with the population register with a unique personal 
identifier, the citizen service number. Data from the 
national medical register, Statistics Netherlands, and 
the Netherlands perinatal registry were linked to the 
population register by using probability matching, 
based on sex, date of birth, and postcode. For the 
national medical register, unique records were 
successfully linked, ranging from 97.3% in 2005 to 
98.7% in 2012.45
Population for analysis
For the present study, vaccination data from 
1 356 926 Dutch children born from 1 January 2005 
to 31 December 2011 who were all eligible for the 
routine immunisation programme were available 
from the electronic national immunisation register 
Præventis (fig 1). Of these children, 93% received 
the first four recommended DTaP-IPV-Hib+PCV 
vaccines and were eligible for inclusion in this study. 
We excluded children who did not receive these DTP 
containing vaccinations (n=102 422) to limit the 
possibility of bias attributable to factors related to 
low vaccination coverage (such as refusal based on 
religion). We also excluded children who received the 
fourth DTaPIPVHib+PCV vaccine either before age 
9 months (n=322), after age 20 months (n=5235), 
after 31 December 2012 (n=2586), after the MMR 
vaccine (n=18 110), or simultaneously with the MMR 
vaccine (n=4333). In addition, we excluded children 
who received an MMR vaccine before age 12 months 
(n=44 965) because these children are recommended 
to receive another MMR vaccine at 14 months and 
therefore follow a different vaccination schedule 
than the other children in the study population. 
After exclusion of children with a birth weight <500 
g (n=31), missing data on covariates (birth weight, 
gestational age, maternal age, parental country of 
birth, and postal code) (n=81 389), or missing data 
because of migration (n=939), 1 096 594 children 
(81%) remained for analysis.
Statistical analysis
Main analysis
Cox proportional hazards models were used to 
estimate hazard ratios for hospital admissions related 
to infectious disease according to the most recent 
vaccination (MMR+MenC versus fourth DTaP-IPV-
Hib+PCV), with last received vaccination included as 
a time varying variable changing at the age of receipt 
of the MMR+MenC vaccine (statistical code provided 
in appendix 2). Children entered the model at the 
age of receipt of the fourth DTaP-IPV-Hib+PCV and 
were followed until the age of hospital admission for 
infection (in case of an event) or were censored at 
death, age 24 months, age of emigration, or age on 31 
December 2012, whichever came first. Age was used 
as timescale for the Cox regression. We included age 
at MMR+MenC vaccination as a time variable exposure 
and used age as a timescale in the Cox regression; 
this effectively means that at each age (in days) we 
compared children who had already received the 
MMR+MenC vaccine with children who had not yet 
received the MMR+MenC vaccine, thereby adjusting 
for age.
Analyses were stratified by date of birth to 
fully control for age, season, and calendar year. 
Associations were adjusted for sex, chronic diseases 
(Y/N) before baseline (age 9 months; list of ICD-9 
codes, shown in table C in appendix 1), admission to 
hospital for any reason in the month before baseline 
(the fourth DTaP-IPV-Hib+PCV is received from age 9 
months onwards, a fixed month of 8 months of age 
was chosen for this variable) (Y/N), birth weight, 
gestational age, maternal age and parity (1, 2, 3, and 
≥4), parents’ country of birth (two Dutch parents, one 
Dutch and one non-Dutch parent, and two non-Dutch 
parents), and postcode in three digits. Analyses were 
stratified by type of infection—for instance, upper 
respiratory, lower respiratory, gastrointestinal, and 
other infections. Sex and birth year were examined 
as potential effect modifiers by an interaction test and 
stratified analysis. Because a lot of data were missing 
for level of parental educational, we additionally 
adjusted associations for level (low, medium, or 
Children in study population (n=1 356 926)
Children in nal study population (n=1 096 594)
Excluded (n=260 332):
  Did not receive four recommended DTaP-IPV-Hib
    vaccines (n=102 422)
  Received 4th DTaP-IPV-Hib vaccine before age
    9 months (n=322)
  Received 4th DTaP-IPV-Hib vaccine before age
    20 months (n=5235)
  Received 4th DTaP-IPV-Hib vaccine aer
    31 December 2012 (n=2586)
  Received MMR vaccine before age 12 months,
    before 4th DTaP-IPV-Hib vaccine, or simultaneously
    with 4th DTaP-IPV-Hib vaccine (n=67 408)
  Had birth weight <500 g (n=31)
  Had missing data on covariates (birth weight,
    gestational age, maternal age, parental country of
    birth, and postcode) (n=81 389)
  Missing data because of migration (n=939)
Fig 1 | Flow chart of children included in study population 
according to compliance with vaccination schedule
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high) in a subsample of 79% of eligible children with 
complete information.
The same analysis was performed with admission 
for injury or poisoning (ICD-9-CM codes 800-999) as a 
negative control outcome.46
Analyses were performed with SAS version 9.2 (SAS 
Institute, Cary, NC) and Stata 14 (StataCorp, College 
Station, TX).
Sensitivity analyses
Firstly, we performed the same analysis as described 
above with all hospital admissions for infections taken 
into account, thus also including day admissions 
without an overnight stay.
Secondly, we performed another analysis taking 
into account repeated hospital admissions with 
the Andersen-Gill model47 as an extension of the 
Cox model. We excluded all hospital admissions 
for infection that occurred less than 14 days after 
a previous discharge because multiple admissions 
within a short period could be attributable to the same 
infection. In cases of a previous hospital admission, 
children re-entered the study 14 days after discharge 
and were followed until a next admission or censored 
at death, age 24 months, or age at 31 December 2012, 
whichever came first.
In a third analysis, we compared the fourth with 
the third DTaP-IPV-Hib+PCV vaccination. Vaccination 
was included as a time varying variable changing at 
the age of the fourth vaccination. Children entered the 
model from the age of receipt of the third vaccination 
and were followed until the age of admission for 
infection or were censored at death, age of MMR+MenC 
vaccination, age 14 months, or age on 31 December 
2012, whichever came first.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, or 
implementation of the study. No patients were asked to 
advise on interpretation or writing up of results. There 
are no plans to disseminate the results of the research 
to study participants or the relevant patient community.
Results
Study population
Table 2 shows characteristics of the 1 096 594 children 
included in the analyses. Children received the fourth 
DTaP-IPV-Hib+PCV vaccination at a median age of 11.2 
months and the MMR+MenC vaccination at a median 
age of 14.3 months. Almost all children received the 
MMR vaccination (99.6%) (fig 2), and about 99% of all 
children received PCV with the DTaP-IPV-Hib vaccines 
and the MenC vaccine with the MMR vaccine. Most 
children had at least one Dutch parent (89.1%), and 
about half of the children had at least one parent with 
higher education (51.1% of all children with data on 
parental educational level). About 1% of all children 
were admitted to hospital for any reason at age 8 
months, and 2.5% had previously had a diagnosis of a 
chronic disease before receipt of the fourth DTaP-IPV-
Hib+PCV vaccine.
MMR+MenC v fourth DTaP-IPV-Hib+PCV in relation 
to admission for infection (main analysis)
During 1 061 242 person years of follow-up, 10 961 
children were admitted to hospital for more than one 
day (this was 26% of all admissions for infection, 
meaning that 74% of all admissions for infection 
were day admissions) for an infection (admission rate 
10/1000 person years). Admission rates declined with 
age, from 15/1000 person years at age 12 months to 
7/1000 person years at age 24 months (fig 3). Similarly, 
admission rates declined with age in those who 
received MMR+MenC as their most recent vaccination 
(average admission rate of 9/1000 person years). In 
children whose most recent vaccination was the fourth 
DTaP-IPV-Hib+PCV, admission rates slightly declined 
Table 2 | Characteristics of 1 096 594 Dutch children included in study of infections after 
vaccination. Figures are numbers (percentage) unless stated otherwise
Data
Median (IQR) age at fourth DTaP-IPV-Hib vaccination (months) 11.2 (11.0-11.6)
Median (IQR) age at MMR vaccination (months)* 14.3 (14.0-14.8)
Boys 561 407 (51.2)
Median (IQR) birth weight (g) 3460 (3100-3810)
Median (IQR) gestational age (weeks) 39.9 (38.7-40.7)
Median (IQR) maternal age at birth of child (years) 31 (27-34)
Maternal parity†:
 One 505 851 (46.1)
 Two 400 703 (36.5)
 Three 138 565 (12.6)
 Four or more 51 473 (4.7)
Highest parental educational level‡:
 Low 115 205 (13.2)
 Medium 310 445 (35.6)
 High 445 544 (51.1)
Parental country of birth:
 Netherlands 834 580 (76.1)
 Netherlands and foreign 142 555 (13.0)
 Foreign 119 457 (10.9)
Chronic disease of child 27 430 (2.5)
Hospital admission for any reason at age 8 months 11 706 (1.1)
IQR=interquartile range.
* Data available for 1 092 625 children.
† Represents number of childbirths of mother.

























Fig 2 | Proportion of children according to most recent 
vaccination with DTaP-IPV-Hib+PCV and MMR+MenC, 
based on 1 096 594 children included in present study
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until 14 months, which is the median age of receipt 
of MMR+MenC, and increased thereafter until age 17 
months. Admission rates at age 17 months were 1.8 
times higher in those whose most recent vaccination 
was the fourth DTaPIPVHib+PCV, compared with the 
overall admission rates (20/1000 v 11/1000 person 
years). The average admission rate in those whose most 
recent vaccination was the fourth DTaP-IPV-Hib+PCV 
was 14/1000 person years.
Compared with the fourth DTaP-IPV-Hib+PCV as 
most recent vaccination, receipt of MMR+MenC as 
the most recent vaccination was associated with a 
age adjusted hazard ratio of 0.60 (95% confidence 
interval 0.55 to 0.65) for hospital admissions related to 
infectious disease (table 3). After additional adjustment 
for sex, chronic disease, admissions at age 8 months, 
birth weight, gestational age, maternal age and parity, 
parents’ country of birth, and postcode, the hazard 
ratio was 0.62 (0.57 to 0.67). No effect modification 
was observed for sex (P=0.55 for interaction) and birth 
cohort (P=0.29 for interaction) (table D in appendix 1). 
Additional adjustment for level of parents’ educational 
in the subsample of children with available data 
changed the results marginally (0.64, 0.58 to 0.70). 
When we took repeated hospital admissions for 
infections into account (event rate 11/1000 person 
years), the adjusted hazard ratio (0.72, 0.66 to 0.79) 
was slightly increased.
Type of infection
Of all 10 961 hospital admissions related to infection, 
43% were for gastrointestinal infections, 40% for 
upper respiratory infections, 31% for lower respiratory 
infections, and 17% for other infections. The 
hazard ratio for admission according to most recent 
vaccination ranged between 0.54 (95% confidence 
interval 0.48 to 0.62) for upper respiratory infections to 
0.70 (95% 0.61 to 0.80) for gastrointestinal infections 
(table E in appendix 1).
All admissions (including day admissions)
When we took into account all hospital admissions 
for infections, including day admissions without 
an overnight stay, 41 976 children were admitted 


















Fourth DTaP-IPV-Hib+PCV v MMR+MenC























Third v fourth DTaP-IPV-Hib+PCV














Fig 3 | Hospital admissions rates for infection with 95% 
confidence intervals for fourth DTaP-IPV-Hib+PCV v 
MMR+MenC as most recently received vaccination (in 
top panel line for fourth DTaP-IPV-Hib+PCV represents 
admission rate in children who had not yet received 
MMR+MenC vaccination) and for third v fourth DTaP-IPV-
Hib+PCV (bottom panel). Dashed vertical lines represent 
recommended age of vaccination (top: MMR+MenC 
at age 14 months; bottom: fourth DTaPIPVHib+PCV at 
age 11 months). Each estimate represents incidence of 
month before that month—for example, estimate at age 
12 months comprises incidence for age 335-364 days. 
Note that incidence of admissions for MMR vaccinated 
individuals aged 12-14 months was not reported 
because too few children in study population received 
MMR at age 12-14 months (see fig 2), and, of these, 
<10 were admitted to hospital for infection. Because of 
privacy reasons, we cannot report data that apply to <10 
individuals
Table 3 | Hazard ratio (95% CI) for hospital admissions (>1 day) for infections (outcome of interest) and for injuries 
or poisoning (negative control outcome) according to most recent vaccination
Outcome
Most recent vaccination Events/person years
HR (95% CI)*
Age adjusted Fully adjusted†
Infections Fourth DTaP-IPV-Hib+PCV 4111/284 786 1.00 1.00
MMR+MenC 6850/776 456 0.60 (0.55 to 0.65) 0.62 (0.57 to 0.67)
Injuries or poisoning Fourth DTaP-IPV-Hib+PCV 3605/285 676 1.00 1.00
MMR+MenC 5150/782 738 0.81 (0.71 to 0.93) 0.84 (0.73 to 0.96)
Infections Third DTaP-IPV-Hib+PCV 10 654/639 484 1.00 1.00
Fourth DTaP-IPV-Hib+PCV 3185/231 001 0.66 (0.60 to 0.72) 0.69 (0.63 to 0.76)‡
* Hazard ratios from Cox regression with age as underlying time scale and stratified for date of birth.
† Adjusted for sex, chronic disease, admission for any reason at age 8 months, birth weight, gestational age, maternal age and parity, parental country 
of birth, and postcode.
‡ Adjusted for sex, chronic disease, birth weight, gestational age, maternal age and parity, parental country of birth, and postcode.
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years of follow-up. Of these admissions, 83% were 
for upper respiratory infections, 9% for lower 
respiratory infections, 12% for gastrointestinal 
infections, and 6% for other infections. Receipt of 
MMR+MenC as the most recent vaccination instead 
of the fourth DTaP-IPV-Hib+PCV was associated 
with a fully adjusted hazard ratio of 0.40 (95% 
confidence interval 0.38 to 0.41) for hospital 
admissions related to infectious disease, which was 
driven mainly by upper respiratory infections (table 
F in appendix 2).
Negative control outcome
During 1 068 414 person years of follow-up, 5150 
children were admitted to hospital for more than one 
day because of injury or poisoning (negative control 
outcome). After full adjustment, we observed the 
hazard ratio was 0.84 (95% confidence interval 0.73 
to 0.96) for admission for injuries or poisoning with 
MMR+MenC as the most recent vaccination compared 
with the fourth DTaP-IPV-Hib+PCV as most recent 
vaccination (table 3). When we also considered 
admissions without an overnight stay, the fully 
adjusted hazard ratio was 0.80 (0.71 to 0.89) (table F 
in appendix 1).
Fourth v third DTaP-IPV-Hib+PCV in relation to 
hospital admission for infection
During 870 485 person years of follow-up, 13 839 
children were admitted for more than one day for 
infection (admission rate 16/1000 person years). The 
average admission rate in those with the fourth DTaP-
IPV-Hib+PCV as their most recent vaccination was 
14/1000 person years. In those with the third DTaP-IPV-
Hib+PCV as their most recent vaccination, admission 
rates were quite stable until age 11 months, which is 
the median age of receipt of the fourth vaccination, 
and increased thereafter until age 14 months (fig 3). 
Admission rates at age 14 months were 1.5 times 
higher in those with the third DTaP-IPV-Hib+PCV 
as their most recent vaccination compared with the 
overall admission rates (19/1000 v 13/1000 person 
years). The average admission rate in those with third 
vaccination as their most recent was 17/1000 person 
years.
Receipt of the fourth DTaP-IPV-Hib+PCV as the 
most recent vaccination was associated with a age 
adjusted hazard ratio of 0.66 (95% confidence interval 
0.60 to 0.72) for hospital admissions for infectious 
disease compared with the third DTaP-IPV-Hib+PCV 
vaccination as the most recent (table 3). After additional 
adjustment for sex, chronic disease, birth weight, 
gestational age, maternal age, parity, parents’ country 
of birth, and postcode, the hazard ratio was 0.69 
(0.63 to 0.76). When we took into account admissions 
without an overnight stay, the fully adjusted hazard 
ratio was 0.48 (0.46 to 0.51) (table F in appendix 1). 
The adjusted hazard ratios by type of infection ranged 
from 0.59 (0.47 to 0.74) for other infections to 0.79 
(0.67 to 0.92) for lower respiratory infections (table E 
in appendix 1).
discussion
In more than a million Dutch children aged 11-
24 months, there was a 38% lower rate of hospital 
admissions related to infectious disease in those who 
had MMR+MenC as their most recent vaccination, 
compared with those who had DTaP-IPV-Hib+PCV 
as their most recent vaccination. We also observed a 
16% lower rate of admission for injuries or poisoning 
(negative control outcome) in children with MMR+MenC 
as their most recent vaccination. Moreover, there was 
a 31% lower rate of admissions related to infectious 
disease for children with the fourth DTaP-IPV-Hib+PCV 
as their most recent vaccination, compared with the 
third as their most recent vaccine. These findings 
suggest that a lower rate of admission is associated with 
adherence to the routinely recommended schedule. It 
is likely that healthy vaccinee bias was present and (at 
least partly) explains the lower rate of infections that 
we observed for receipt of an additional vaccine, rather 
than being an effect of specifically receiving MMR. 
The findings of this large scale observational study on 
non-specific effects emphasise the extreme difficulty in 
interpreting such results given the likely presence of 
healthy vaccinee bias.
We observed that after the median age of receipt of 
the next vaccine, which was MMR+MenC at 14 months 
in the MMR+MenC versus DTaP-IPV-Hib+PCV analysis 
and the fourth DTaP-IPV-Hib+PCV at 11 months in 
the analysis of fourth versus third DTaP-IPV-Hib+PCV, 
admission rates among those who deviated from the 
recommended schedule suddenly increased compared 
with the overall admissions rates. This suggests that 
vaccination is postponed in children who are more 
prone to admission. The confounders that we included 
in the analysis did not considerably change the hazard 
ratio, so apparently these confounders do not explain 
the increased risk of admission in children in whom 
vaccination is postponed. An unmeasured confounder 
could be acute illness, which might be associated with 
timing of vaccination and rate of admission. The lower 
rate of admission for infection for the fourth DTaP-IPV-
Hib+PCV as most recent vaccination compared with 
the third also suggests that receipt of an additional 
vaccination (and therefore adherence to the routinely 
recommended schedule) is followed by a lower rate of 
admission, and this is thus not a finding that can be 
attributed to MMR specifically. This raises concerns for 
past and future observational studies on non-specific 
effects and emphasises that evidence from randomised 
trials that also investigate different sequences of 
vaccines is needed to draw conclusions on this matter, 
as was concluded by the recently published WHO-
SAGE review.21
In a nationwide population based cohort of about 
500 000 Danish children,10 the rate of hospital 
admissions related to infectious disease was 14% 
lower in those with MMR as their most recent 
vaccination compared with DTaP-IPV-Hib as their most 
recent vaccination. Their report of non-specific effects 
of MMR vaccination was strengthened by the fact that 
they found a 62% higher rate of hospital admissions 
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related to infectious disease in children who received 
DTaP-IPV-Hib after MMR vaccination, and they did 
not find any effect of MMR vaccination on emergency 
department visits after unintentional injury. A 
difference between the Danish study and our study is 
that there was more variation in the Danish studyin the 
age at MMR vaccination (median 15.8 (interquartile 
range15.2-17.0) v 14.3 (14.0-14.8)), which could be 
attributed to a different vaccination system. In the 
Netherlands, appointments for each vaccination are 
made in child health clinics in advance. In Denmark, 
parents have to make an appointment with the GP 
themselves for their children to receive vaccinations. 
This might have led to more random variation in the 
age at MMR vaccination and therefore proportionally 
less variation from factors related to the child’s health 
in Denmark than in the Netherlands. The system in the 
Netherlands, with a more fixed schedule as result of 
prescheduled appointments, more clearly shows the 
existence of healthy vaccinee bias. This could explain 
the discrepancy between findings. It seems likely, 
however, that healthy vaccinee bias is also present in 
the Danish study. We therefore consider it likely that 
the lower rate of infection as estimated in the Danish 
setting overestimates any non-specific effects.
Several randomised controlled trials have been 
performed in low income countries to assess non-
specific effects of vaccines containing measles on all 
cause mortality. The pooled relative risk from four 
randomised controlled trials was 0.74 (95% confidence 
interval 0.51 to 1.07), pointing towards beneficial 
effects of receipt of such vaccines.21 Like these 
vaccines, BCG vaccination, another live attenuated 
vaccine, has also been associated with non-specific 
effects in low income countries.21 A recently published 
randomised controlled study on BCG vaccination at 
birth in Denmark, however, did not find an effect on 
all cause hospital admissions48 or childhood infections 
reported by parents.49
Although we show that healthy vaccinee bias is 
probably present in our analysis, the impact of this 
bias is hard to quantify, and we cannot exclude that 
non-specific effects are still present in our study. If we 
assume that the lower rate of infection after the fourth 
versus the third DTaP-IPV-Hib+PCV vaccination is due 
to healthy vaccinee bias, the difference in hazard ratios 
between the MMR+MenC versus DTaP-IPV-Hib+PCV 
(hazard ratio of 0.62, 95% confidence interval 0.57 
to 0.67) and the fourth versus the third DTaP-IPV-
Hib+PCV (0.69, 0.63 to 0.76) could be ascribed to non-
specific effects. Furthermore, in the MMR+MenC versus 
DTaP-IPV-Hib+PCV analysis the effect was stronger 
for respiratory infections than for other infections, 
but this was not the case for the fourth versus the 
third DTaP-IPV-Hib+PCV analysis. As non-specific 
effects have been found to be stronger for respiratory 
infections,10  19 these findings could indicate the 
presence of non-specific effects of MMR. This is rather 
indirect evidence, comparing different populations 
of children, however, and therefore not robust. These 
findings emphasise the difficulty of investigating non-
specific effects of vaccination in observational studies. 
This is also confirmed by our findings for the negative 
control outcome. We observed a 14% (95% confidence 
interval 4% to 27%) lower rate of admission for 
injuries or poisoning, which can obviously not be 
explained by non-specific effects. This finding could 
also be explained by healthy vaccinee bias but to a 
lesser extent.
It should be noted that in the Netherlands, the DTaP-
IPV-Hib vaccine is administered with a multivalent 
conjugate vaccination against pneumococcal disease 
and the MMR vaccine is administered with vaccination 
against MenC. We cannot exclude the possibility that 
beneficial non-specific effects of the live MMR vaccine 
were masked by the simultaneous co-administration 
of the attenuated MenC vaccine. The Danish study 
that reported non-specific effects of MMR vaccination 
studied only MMR vaccination and not the combination 
of MMR and MenC, which could also explain the 
different findings with our study. Other European 
countries might also have the opportunity to study 
non-specific effects of vaccination and the potential 
for healthy vaccinee bias. As in the Netherlands, many 
European countries first give a vaccine containing DTP, 
mostly around age 12 months, and thereafter a MMR 
vaccine at age 15-18 months (ECDC: http://vaccine-
schedule.ecdc.europa.eu/). There are also some 
countries, however, that first give the MMR vaccine 
and then the DTP vaccine, although in most of these 
countries the MMR vaccine is given together with 
PCV or MenC vaccination. Nevertheless, it would be 
interesting to see the results of a similar analysis from 
countries with a “reversed” schedule.
Strengths and weaknesses of study
A major strength of our study is that it is nationwide 
population based and included more than a million 
children. Because nearly all children received both 
the DTaP-IPV-Hib+PCV and MMR+MenC vaccinations, 
children acted as their own controls. Analyses were 
stratified by date of birth to fully control for age, year, 
and season. The large sample size enabled us to perform 
multiple stratified analyses. Moreover, the Dutch 
vaccination system, which is characterised by its fixed 
schedule as a result of prescheduled appointments, 
provided the opportunity to explore and illustrate 
the presence of healthy vaccinee bias. A limitation of 
the study is that we did not have information on the 
reason for delayed vaccination. Moreover, it should be 
noted that not all hospital admissions were captured 
in the national medication registration and that 
completeness decreased with time (97% in 2005 to 
75% in 2012).44 We assumed that the completeness 
was not associated with the timing of vaccination in our 
study and therefore would not confound the results. 
The interaction test confirmed this; we observed no 
effect modification for birth cohort. As these findings 
were based on admission data, we took only severely 
affected children into account. Therefore, it would be 
of interest to investigate the association between most 
recent vaccination and GP consultations for infections. 
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As this would enable us to take into account acute 
illness (for example, a GP visit for fever, as vaccination 
should be avoided if a child’s temperature is ≥38.5°C50) 
as a time varying variable, it could provide more 
insight in the effect of acute illness as part of healthy 
vaccinee bias.
In conclusion, throughout the world vaccination has 
contributed to a decline in mortality and morbidity 
as result of specific vaccine effects. Evidence for non-
specific effects, however, particularly in high income 
countries, remains uncertain. In our observational 
study on non-specific effects of vaccination in 
more than a million Dutch children, a lower rate of 
hospital admission for infection followed receipt of an 
additional vaccination (and therefore adherence to the 
routinely recommended schedule) and could not be 
attributed to MMR specifically. Receipt of MMR+MenC 
as most recent vaccination was associated with a 38% 
lower rate of admission related to infectious disease, 
compared with DTaP-IPV-Hib+PCV as most recent 
vaccination. We also observed a 31% lower rate of 
admission for infection with receipt of the fourth DTaP-
IPV-Hib+PCV as most recent vaccination, compared 
with the third as most recent vaccination. These 
findings, together with those for the negative control 
outcome, suggest that the delay of a vaccination (be 
it DTaP-IPV-Hib+PCV or MMR+MenC) might depend 
on the health status of a child, rather than the other 
way around. We cannot exclude the presence of 
non-specific effects of MMR vaccination, but we are 
unable to disentangle the possible non-specific effects 
from bias. Our findings emphasise the importance of 
interpreting findings from observational studies on 
non-specific effects of vaccination with great caution.
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